نتائج البحث - "Sorokin, I."

1

دورية أكاديمية

Clinical and morphological features of non-muscle invasive bladder cancer: implications for treatment, prognosis and relapse of the disease (literature review) ; Клинико-морфологические особенности немышечноинвазивного рака мочевого пузыря: влияние на лечение, прогноз и рецидив заболевания (обзор литературы)

المؤلفون: A. Pshikhachev M., L. Mikhaleva M., M. Gusniev A., V. Pechnikova V., N. Polyanko I., N. Sorokin I., A. Kamalov A., А. Пшихачев М., Л. Михалева М., М. Гусниев А., В. Печникова В., Н. Полянко И., Н. Сорокин И., А. Камалов А.

المصدر: Cancer Urology; Том 17, № 1 (2021); 134-141 ; Онкоурология; Том 17, № 1 (2021); 134-141 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: bladder cancer, non-muscle invasive cancer, oncology, morphology, рак мочевого пузыря, немышечно-инвазивный рак, онкология, морфология

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/1339/1261Test; Kamat A.M., Bagcioglu M., Huri E. What is new in non-muscle-invasive bladder cancer in 2016? Turk J Urology 2017;43(1):9-13. DOI:10.5152/tud.2017.60376.; Anastasiadis A., de Reijke T.M. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4(1):13-32. DOI:10.1177/1756287211431976.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.; Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология 2019;15(2):15-24. DOI:10.17650/1726-9776-2019-15-2-15-24.; Hendricksen K., Witjes J.A. Treatment of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC). Eur Urol Suppl 2007;6(14):800-8. DOI:10.1016/j.eursup.2007.04.008.; Kassouf W., Traboulsi S.L., Kulkarni G.S. et al. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015;9(9-10):690-704. DOI:10.5489/cuaj.3320.; Biluts H., Minas E. Bladder Tumours at Tikur Anbessa Hospital in Ethiopia. East Central African J Surgery 2011;16(1). Available at: https://www.ajol.info/index.php/ecajs/article/view/72487Test.; Adeloye D., Harhay M.O., Ayepola O.O. et al. Estimate of the incidence of bladder cancer in Africa: a systematic review and Bayesian meta-analysis. Int J Urol 2019;26(1):102-12. DOI:10.1111/iju.13824.; Shen P.L., Lin M.E., Hong Y.K. et al. Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies. World J Surg Oncol 2018;16(1):197. DOI:10.1186/s12957-018-1497-0.; Abdollah F., Gandaglia G., Thuret R. et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37(3):219-25. DOI:10.1016/j.canep.2013.02.002.; Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30. DOI:10.3322/caac.21387.; Moschini M., D'Andrea D., Korn S. et al. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol 2017;14(11):651-68. DOI:10.1038/nrurol.2017.125.; Baumeister P., Zamboni S., Mattei A. et al. Histological variants in nonmuscle invasive bladder cancer. Transl Androl Urol 2019;8(1):34-8. DOI:10.21037/tau.2019.01.09.; Audenet F., Attalla K., Sfakianos J.P. The evolution of bladder cancer genomics: What have we learned and how can we use it? Urol Oncol 2018;36(7):313-20. DOI:10.1016/j.urolonc.2018.02.017.; Amin M.B., McKenney J.K. An approach to the diagnosis of flat intraepithelial lesions of the urinary bladder using the World Health Organization/International Society of Urological Pathology consensus classification system. Adv Anatomic Pathol 2002;9(4):222-32. DOI:10.1097/00125480-200207000-00002.; Humphrey P.A., Moch H., Cubilla A.L. et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur Urol 2016;70(1):106-19. DOI:10.1016/j.eururo.2016.02.028.; Felix A.S., Soliman A., Wilson M. et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 2008;19(4):421-9. DOI:10.1007/s10552-007-9104-7.; Manunta A., Vincendeau S., Kiriakou G. et al. Non-transitional cell bladder carcinomas. BJU international 2005;95(4):497-502. DOI:10.1111/j.1464-410X.2005.05327.x.; Abol-Enein H., Kava B.R., Carmack A.J.K. Nonurothelial cancer of the bladder. Urology 2007;69(1):93-104. DOI:10.1016/j.urology.2006.08.1107.; El-Mekresh M.M., el-Baz M.A., Ghoneim M.A. et al. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br J Urol 1998;82(2):206-12. DOI:10.1046/j.1464-410x.1998.00718.x.; Grignon D.J., Ro J.Y., Ayala A.G. et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67(8):2165-72. DOI:10.1002/1097-0142(19910415)67:83.0.co;2-m.; Sved P., Gomez P., Manoharan M. et al. Small cell carcinoma of the bladder. BJU Int 2004;94(1):12-7. DOI:10.1111/j.1464-410X.2003.04893.x.; Hansel D.E., Amin M.A., Comperat E. et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol 2013;63(2):321-32. DOI:10.1016/j.eururo.2012.10.008.; Cheng L., Zhang S., Alexander R. et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol 2011;35(5):34-46. DOI:10.1097/PAS.0b013e3182159dec.; Amin M.B., Ro J.Y., el-Sharkawy T. et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994;18(12):1224-32. DOI:10.1097/00000478-199412000-00005.; Moschini M., Dell'Oglio P., Luciano R. et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 2017;35(6):335-41. DOI:10.1016/j.urolonc.2016.12.006.; Beltran A.L., Cheng L., Montironi R. et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch 2014;465(2):199-205. DOI:10.1007/s00428-014-1601-y.; Talbert M.L., Young R.H. Carcinomas of the urinary bladder with deceptively benign-appearing foci. A report of three cases. Am J Surg Pathol 1989;13(5):374-81. DOI:10.1097/00000478-19890500000004.; Young R.H., Oliva E. Transitional cell carcinomas of the urinary bladder that may be underdiagnosed. A report of four invasive cases exemplifying the homology between neoplastic and non-neoplastic transitional cell lesions. Am J Surg Pathol 1996;20(12):1448-54. DOI:10.1097/00000478-199612000-00003.; Gofrit O.N., Pode D., Pizov G. et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol 2009;27(3):258-62. DOI:10.1016/j.urolonc.2007.12.011.; Yang Z., Epstein J.I. Urothelial carcinoma in situ of the bladder with glandular differentiation: report of 92 cases. Am J Surg Pathol 2018;42(7):971-6. DOI:10.1097/PAS.0000000000001073.; Reis H., Krafft U., Niedworok C. et al. Biomarkers in urachal cancer and adenocarcinomas in the bladder: a comprehensive review supplemented by own data. Dis Markers 2018;2018:7308168. DOI:10.1155/2018/7308168.; Wick M.R. Primary lesions that may imitate metastatic tumors histologically: a selective review. Sem Diagn Pathol 2018;35(2):123-42. DOI:10.1053/j.semdp.2017.11.010.; Cheng L., Cheville J.C., Neumann R.M. et al. Flat intraepithelial lesions of the urinary bladder. Cancer 2000;88(3):625-31.; Murata S., Iseki M., Kinjo M. et al. Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder. Am J Clin Pathol 2010;134(6):862-72. DOI:10.1309/AJCPACNUDWEN9GN4.; McKenney J.K. Precursor lesions of the urinary bladder. Histopathology 2019;74(1):68-76. DOI:10.1111/his.13762.; Babjuk M., Burger M., Comperat E.M. et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol 2019;76(5):639-57. DOI:10.1016/j.eururo.2019.08.016.; Kirkali Z., Chan T., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4-34. DOI:10.1016/j.urology.2005.07.062.; Dobruch J., Borowka A., Herr H.W. Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 2014;84(4):881-5. DOI:10.1016/j.urology.2014.06.005.; Schroeck F.R., Lynch K.E., Li Z. et al. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, nonmuscle-invasive bladder cancer. Cancer 2019;125(18):3147-54. DOI:10.1002/cncr.32185.; Семенов Э.В., Мазаев А.В., Зуков Р.А., Куртасова Л.М. Факторы прогноза у больных раком мочевого пузыря. Сибирское медицинское обозрение 2015;(5):13-22. DOI:10.20333/25000136-2015-5-13-22.; Simon M., Bosset P.O., Rouanne M. et al. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PloS One 2019;14(2):e0211721. DOI:10.1371/journal.pone.0211721.; Aydin M., Bitkin A., Kadihasanoglu M. et al. Correlation of neutrophil-lymphocyte ratio and risk scores in non-muscle invasive bladder cancer. Actas Urol Esp 2019;43(9):503-8. DOI:10.1016/j.acuro.2018.12.004.; Синицина О.В., Чонкина А.А., Илюшкина М.В. и др. Молекулярно-генетическая методика оценки риска неблагоприятного течения заболевания при поверхностном раке мочевого пузыря. Медицинский алфавит 2014;3(15):56-7.; Lee A., Lee H. J., Huang H.H. et al. Low-risk non-muscle-invasive bladder cancer: Further prognostic stratification into the “very-low-risk” group based on tumor size. Int J Urol 2019;26(4):481-6. DOI:10.1111/iju.13913.; Morera D.S., Hasanali S.L., Belew D. et al. Clinical parameters outperform molecular subtypes for predicting outcome in bladder cancer: results from multiple cohorts, including TCGA. J Urol 2020;203(1):62-72. DOI:10.1097/JU.0000000000000351.; Воробцова И.Е., Васильева З.Ж., Коузова Е.Д. и др. Диагностика рецидивов рака мочевого пузыря с помощью FISH-метода, осуществляемого на клетках осадка мочи. Онкоурология 2013;9(2):35-41. DOI:10.17650/1726-9776-2013-9-2-35-41.; Dadhania V., Zhang M., Zhang L. et al. Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 2016;12:105-17. DOI:10.1016/j.ebiom.2016.08.036.; Kessel K.E.M., van der Keur K.A., Dyrskj0t L. et al. Molecular markers increase precision of the European Association of Urology non-muscle-invasive bladder cancer progression risk groups. Clin Cancer Res 2018;24(7):1586-93. DOI:10.1158/1078-0432.CCR-17-2719.; Al-Maghrabi J.A., Qureshi I.A., Khabaz M.N. Immunhistochemical expression of GLUT1 is associated with low grade and low stage of urinary bladder cancer. Int J Clin Exp Pathol 2019;12(8):3049-57.; Yasui M., Kawahara T., Izumi K. et al. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer. BMC Cancer 2019;19(1):331. DOI:10.1186/s12885-019-5512-9.; Chen M.K., Chen Z.J., Xiao K.H. et al. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer. Japan J Clin Oncol 2020;4(50):456-64. DOI:10.1093/jjco/hyz186.; Descotes F., Kara N., Decaussin-Petrucci M. et al. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine. Br J Cancer 2017;117(4):583-7. DOI:10.1038/bjc.2017.210.; He Y., Wang N., Zhou X. et al. Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review. BMJ Open 2018;8(4):e019635. DOI:10.1136/bmjopen-2017-019635.; Mossanen M., Wang Y., Szymaniak J. et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol 2019;37(10):2059-65. DOI:10.1007/s00345-018-2550-x.; https://oncourology.abvpress.ru/oncur/article/view/1339Test

الإتاحة: https://doi.org/10.17650/1726-9776-2021-17-1-134-141Test
https://doi.org/10.1177/1756287211431976Test
https://doi.org/10.17650/1726-9776-2019-15-2-15-24Test
https://doi.org/10.1016/j.eursup.2007.04.008Test
https://doi.org/10.5489/cuaj.3320Test
https://doi.org/10.1111/iju.13824Test
https://doi.org/10.1186/s12957-018-1497-0Test
https://doi.org/10.1016/j.canep.2013.02.002Test
https://doi.org/10.3322/caac.21387Test
https://doi.org/10.1038/nrurol.2017.125Test

View record in BASE

2

دورية أكاديمية

Geroprotective properties of neuroprotective and neurotrophic peptides ; Геропротективные свойства нейропротективных и нейротрофических пептидов

المؤلفون: O. Gromova A., I. Torshin Yu., V. Zgoda G., A. Sorokin I., O. Tikhonova V., О. Громова А., И. Торшин Ю., В. Згода Г., А. Сорокин И., О. Тихонова В.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 1 (2020); 61-67 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 1 (2020); 61-67 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-1

مصطلحات موضوعية: geroprotection, neuroprotectors, cerebrolysin, big data, pharmacoinformatics, human kinome, геропротекция, нейропротекторы, церебролизин, большие данные, фармакоинформатика, кином человека

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1263/1000Test; Zeeh J. Medication review – seven steps to improve pharmacotherapy in elderly adults. MMW Fortschr Med. 2016 Jun 9;158(11):54-7. doi:10.1007/s15006-016-8383-x.; Glossmann HH, Lutz OMD. Metformin and Aging: A Review. Gerontology. 2019;65(6):581-590. doi:10.1159/000502257. Epub 2019 Sep 13.; Bornstein NM, Guekht A, Vester J, et al. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials. Neurol Sci. 2018 Apr;39(4):629-640. doi:10.1007/s10072-017-3214-0.; Zhang D, Dong Y, Li Y, et al. Efficacy and Safety of Cerebrolysin for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int. 2017;2017: 4191670. doi:10.1155/2017/4191670.; Ghaffarpasand F, Torabi S, Rasti A, et al. Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2018 Dec 27;15:127-135. doi:10.2147/NDT.S186865. eCollection 2019.; Gauthier S, ProaЦo JV, Jia J, et al. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-47. doi:10.1159/000377672.; Громова ОА, Торшин ИЮ. Мультимодальный эффект церебролизина против воинствующего редукционизма. Неврологический вестник. 2008;(3):83-91.; Chemer N, Bilanovskyi V. Cerebrolysin as a New Treatment Option for Post-Stroke Spasticity: Patient and Physician Perspectives. Neurol Ther. 2019 Jun;8(1):25-27. doi:10.1007/s40120-019-0128-1.; Рохлина МЛ, Козлов АА, Усманова НН, Смирнова ЕА. Применение церебролизина при героиновой наркомании. Психиатрия и психофармакотерапия. 2001;(3):98-102.; Громова ОА, Торшин ИЮ, Згода ВГ, Тихонова ОВ. Комплексный протеомный анализ «легкой» пептидной фракции препарата Церебролизин. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(8): 75-83.; Торшин ИЮ, Громова ОА, Згода ВГ и др. О пептидах Церебролизина, способствующих нормотимии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(12): 68-74.; UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515. doi:10.1093/nar/gky1049.; Torshin IYu. Sensing the change from molecular genetics to personalized medicine. New York: Nova Biomedical Books.; Torshin IY, Rudakov KV. On metric spaces arising during formalization of recognition and classification problems. Part 1: Properties of compactness. Pattern Recognition and Image Analysis. 2016;26(2):274-84.; Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 2: Density properties. Pattern Recognition and Image Analysis. 2016;26(3):483-96.; Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis. 2017;27(2):184-99.; Torshin IYu, Rudakov KV. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis. 2015; 25(4):577-87.; Торшин ИЮ, Громова ОА, Лила АМ и др. Таргетное действие глюкозамина сульфата при сочетании остеоартрита и опухолевой патологии. 2019;(6):23-30.; Schmeisser K, Parker JA. Pleiotropic Effects of mTOR and Autophagy During Development and Aging. Front Cell Dev Biol. 2019 Sep 11;7:192. doi:10.3389/fcell.2019.00192. eCollection 2019.; Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med. 2015 Apr;21(4):395-400. doi:10.1038/nm.3824.; Dephoure N, Zhou C, Villen J, et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008;105(31):10762-7. doi:10.1073/pnas.0805139105.; Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol. 2010;22;20(12):1093-8. doi:10.1016/j.cub.2010.04.041.; Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019 Oct 4; 11(19):8048-8067. doi:10.18632/aging.102355. Epub 2019 Oct 4.; Numazaki M, Tominaga T, Toyooka H, Tominaga M. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem. 2002;277(16):13375-8. doi:10.1074/jbc.C200104200.; Wang S, Ge W, Harns C, et al. Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoRI-HDAC1- mediated regulation of autophagy. J Mol Cell Cardiol. 2018 Jun; 119:40-50. doi:10.1016/j.yjmcc.2018.04.009. Epub 2018 Apr 13.; Ruan X, Arendshorst WJ. Role of protein kinase C in angiotensin II-induced renal vasoconstriction in genetically hypertensive rats. Am J Physiol. 1996 Jun;270(6 Pt 2):F945-52. doi:10.1152/ajprenal.1996.270.6.F945.; Uneda K, Wakui H, Maeda A, et al. Angiotensin II Type 1 Receptor-Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin. J Am Heart Assoc. 2017 Jul 27;6(8). pii: e006120. doi:10.1161/JAHA.117.006120.; Fluhrer R, Friedlein A, Haass C, Walter J. Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. J Biol Chem. 2004 Jan 16;279(3):1585-93. Epub 2003 Oct 22.; Торшин ИЮ, Громова ОА. Экспертный анализ данных в молекулярной фармакологии. Москва: МЦНМО; 2012. 748 с.; Садин АВ, Жидоморов НЮ, Гоголева ИВ и др. Исследование нейрорегенеративного действия церебролизина при травматическом повреждении головного мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(4):57-60.; Yu Z, Zhou X, Wang W, et al. Dynamic phosphorylation of CENP-A at Ser68 orchestrates its cell-cycle-dependent deposition at centromeres. Dev Cell. 2015 Jan 12;32(1):68-81. doi:10.1016/j.devcel.2014.11.030.; Marlier Q, Jibassia F, Verteneuil S, et al. Genetic and pharmacological inhibition of Cdk1 provides neuroprotection towards ischemic neuronal death. Cell Death Discov. 2018 Mar 16;4:43. doi:10.1038/s41420-018-0044-7.; Masuda F, Ishii M, Mori A, et al. Glucose restriction induces transient G2 cell cycle arrest extending cellular chronological lifespan. Sci Rep. 2016 Jan 25;6:19629. doi:10.1038/srep19629.; Hu S, Xie Z, Onishi A, et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell. 2009;139(3):610-22. doi:10.1016/j.cell.2009.08.037.; Chen CH, Wang WJ, Kuo JC, et al. Bidirectional signals transduced by DAPKERK interaction promote the apoptotic effect of DAPK. EMBO J. 2005 Jan 26;24(2):294-304. Epub 2004 Dec 16. doi:10.1038/sj.emboj.7600510.; Nandi S, Reinert LS, Hachem A, et al. Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage. Oncogene. 2007 Apr 5;26(16): 2283-9. doi:10.1038/sj.onc.1210030.; Steiner H, Romig H, Pesold B, et al. Amyloidogenic function of the Alzheimer's disease-associated presenilin 1 in the absence of endoproteolysis. Biochemistry. 1999 Nov 2; 38(44):14600-5. doi:10.1021/bi9914210.; Marambaud P, Shioi J, Serban G, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J. 2002 Apr 15;21(8):1948-56. doi:10.1093/emboj/21.8.1948.; Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2001 Jan;76(1):173-81. doi:10.1046/j.1471-4159.2001.00012.x.; Ye J, Rawson RB, Komuro R, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000 Dec;6(6):1355-64. doi:10.1016/s1097-2765(00)00133-7.; He P, Lee SJ, Lin S, et al. Serum- and glucocorticoid-induced kinase 3 in recycling endosomes mediates acute activation of Na+/H+ exchanger NHE3 by glucocorticoids. Mol Biol Cell. 2011 Oct;22(20):3812-25. doi:10.1091/mbc.E11-04-0328.; Yoo D, Kim BY, Campo C, et al. Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase A. J Biol Chem. 2003 Jun 20;278(25):23066-75. doi:10.1074/jbc.M212301200.; Lee JM, Lee JS, Kim H, et al. EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. Mol Cell. 2012 Nov 30;48(4):572-86. doi:10.1016/j.molcel.2012.09.004.; Tamori Y, Bialucha CU, Tian AG, et al. Involvement of Lgl and Mahjong/VprBP in cell competition. PLoS Biol. 2010 Jul 13;8(7): e1000422. doi:10.1371/journal.pbio.1000422.; Воскресенская ОН, Захаров НБ, Тарасова ЮС и др. О возможных механизмах возникновения когнитивной дисфункции у больных с хроническими формами цереброваскулярных заболеваний. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):32-6. doi:10.14412/2074-2711-2018-1-32-36; Громова ОА, Торшин ИЮ, Федотова ЛЭ. Геронтоинформационный анализ свойств молекулы мексидола. Неврология, нейропсихиатрия, психосоматика. 2017;9(4): 46–54. doi:10.14412/2074-2711-2017-4-46-54.; Торшин ИЮ, Громова ОА, Федотова ЛЭ, Громов АН. Сравнительный хемореактомный анализ декскетопрофена, кетопрофена и диклофенака. Неврология, нейропсихиатрия, психосоматика. 2018;10(1):47–54. doi:10.14412/2074-2711-2018-1-47-54.; https://nnp.ima-press.net/nnp/article/view/1263Test

الإتاحة: https://doi.org/10.14412/2074-2711-2020-1-61-67Test
https://doi.org/10.14412/2074-2711-2020-1Test
https://doi.org/10.1007/s15006-016-8383-xTest
https://doi.org/10.1159/000502257Test
https://doi.org/10.1007/s10072-017-3214-0Test
https://doi.org/10.1155/2017/4191670Test
https://doi.org/10.2147/NDT.S186865Test
https://doi.org/10.1159/000377672Test
https://doi.org/10.1007/s40120-019-0128-1Test
https://doi.org/10.1093/nar/gky1049Test

View record in BASE

3

دورية أكاديمية

Chemotranscriptome analysis of the ethylmethylhydroxypyridine succinate molecule in the context of postgenomic pharmacology ; Хемотранскриптомный анализ молекулы этилметилгидроксипиридина сукцината в контексте постгеномной фармакологии

المؤلفون: O. Gromova A., I. Torshin Yu., A. Sorokin I., V. Semenov A., L. Stakhovskaya V., О. Громова А., И. Торшин Ю., А. Сорокин И., В. Семенов А., Л. Стаховская В.

المساهمون: The investigation has been conducted under Russian Foundation for Basic Research Grants No. 18-07-00944 and No. 19-07-00356, Исследование выполнено при поддержке грантов Российского фонда фундаментальных исследований № 18-07-00944 и 19-07-00356

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 5 (2020); 130-137 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 5 (2020); 130-137 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-5

مصطلحات موضوعية: chemotranscriptomics, ethylmethylhydroxypyridine succinate, data mining, molecular pharmacology, neurons, big data, хемотранскриптомика, этилметилгидроксипиридина сукцинат, интеллектуальный анализ данных, молекулярная фармакология, нейроны, сверхбольшие данные

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/1458/1130Test; Torshin IYu. Sensing the change from molecular genetics to personalized medicine. In: Bioinformatics in the Post-Genomic Era series. NY, USA: Nova Biomedical Books; 2009. ISBN 1-60692-217-0.; Torshin IYu, Rudakov KV. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognition and Image Analysis: Advances in Mathematical Theory and Applications. 2014;24(1):11-23.; Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: factorization approach. Pattern Recognition and Image Analysis: Advances in Mathematical Theory and Applications. 2017;27(1):16-28.; Воронина ТА, Иванова ЕА. Комбинированное применение мексидола с известными лекарственными средствами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(4):115-24. doi:10.17116/jnevro2019119041115; Торшин ИЮ, Громова ОА, Сардарян ИС, Федотова ЛЭ. Сравнительный хемореактомный анализ мексидола. Журнал неврологии и психиатрии им. C.C. Корсакова. 2017;117(1-2):75-83. doi:10.17116/jnevro20171171275-84; Guipponi M, Chentouf A, Webling KE, et al. Galanin pathogenic mutations in temporal lobe epilepsy. Hum Mol Genet. 2015 Jun 1;24(11):3082-91. doi:10.1093/hmg/ddv060. Epub 2015 Feb 17.; Wynick D, Thompson SW, McMahon SB. The role of galanin as a multi-functional neuropeptide in the nervous system. Curr Opin Pharmacol. 2001 Feb;1(1):73-7. doi:10.1016/s1471-4892(01)00006-6; Suarez V, Guntinas-Lichius O, Streppel M, et al. The axotomy-induced neuropeptides galanin and pituitary adenylate cyclase-activating peptide promote axonal sprouting of primary afferent and cranial motor neurones. Eur J Neurosci. 2006;24(6):1555-64 doi:10.1111/j.1460-9568.2006.05029.x; Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem. 2001 May 18;276(20):16772-9. doi:10.1074/jbc.M010660200. Epub 2001 Feb 8.; Brezillon S, Lannoy V, Franssen JD, et al. Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem. 2003;278(2):776-83 doi:10.1074/jbc.M206396200; Gendron L, Perron A, Payet MD. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. Mol Pharmacol. 2004;66(6):1421-30. doi:10.1124/mol.104.002303; Громова ОА, Торшин ИЮ, Федотова ЛЭ. Геронтоинформационный анализ свойств молекулы ЭМГПС. Неврология, нейропсихиатрия, психосоматика. 2017;9(4):46-54. doi:10.14412/2074-2711-2017-4-46-54; Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27;276(5321):2045-7. doi:10.1126/science.276.5321.2045; Mueller KL, Hoon MA, Erlenbach I, et al. The receptors and coding logic for bitter taste. Nature. 2005 Mar 10;434(7030):225-9. doi:10.1038/nature03352; https://nnp.ima-press.net/nnp/article/view/1458Test

الإتاحة: https://doi.org/10.14412/2074-2711-2020-5-130-137Test
https://doi.org/10.14412/2074-2711-2020-5Test
https://doi.org/10.17116/jnevro2019119041115Test
https://doi.org/10.17116/jnevro20171171275-84Test
https://doi.org/10.1093/hmg/ddv060Test
https://doi.org/10.1016/s1471-4892Test(01)00006-6
https://doi.org/10.1111/j.1460-9568.2006.05029.xTest
https://doi.org/10.1074/jbc.M010660200Test
https://doi.org/10.1074/jbc.M206396200Test
https://doi.org/10.1124/mol.104.002303Test

View record in BASE

4

دورية أكاديمية

LASER EN-BLOC RESECTION OF NON-MUSCLE-INVASIVE BLADDER CANCER: CLINICAL AND MORPHOLOGICAL SPECIFICITIES ; ЛАЗЕРНАЯ РЕЗЕКЦИЯ МЫШЕЧНО-НЕИНВАЗИВНЫХ ОПУХОЛЕЙ МОЧЕВОГО ПУЗЫРЯ ЕДИНЫМ БЛОКОМ: КЛИНИКО-МОРФОЛОГИЧЕСКИЕ ПАРАЛЛЕЛИ

المؤلفون: L. Severgina O., N. Sorokin I., A. Dymov M., D. Tsarichenko G., D. Enikeev V., D. Kislyakov A., L. Rapoport M., I. Korovin A., D. Korolev O., Л. Севергина О., Н. Сорокин И., А. Дымов М., Д. Цариченко Г., Д. Еникеев В., Д. Кисляков А., Л. Рапопорт М., И. Коровин А., Д. Королев О.

المصدر: Cancer Urology; Том 14, № 3 (2018); 78-84 ; Онкоурология; Том 14, № 3 (2018); 78-84 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-3

مصطلحات موضوعية: non-muscular invasive bladder cancer, papillary urothelial carcinoma, laser en-bloc resection, substaging of bladder cancer, мышечно-неинвазивный рак мочевого пузыря, папиллярный уротелиальный рак, лазерная резекция опухоли единым блоком, субклассификация рака мочевого пузыря

وصف الملف: application/pdf

العلاقة: https://oncourology.abvpress.ru/oncur/article/view/838/788Test; https://oncourology.abvpress.ru/oncur/article/view/838/801Test; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/838/576Test; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/838/577Test; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/838/578Test; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/838/579Test; EAU Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS). European Association of Urology. Guidelines 2017. Pp. 4–40.; Bryan R.T., Collins S.I., Daykin M.C. et al. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010;92(6):519–524. DOI:10.1308/003588410X12664192076935. PMID: 20522307.; Wu Y.P., Lin T.T., Chen S.H. et al. Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor a meta-analysis. Medicine (Baltimore) 2016;95(45):e5372. DOI:10.1097/MD.0000000000005372. PMID: 27828864.; Kramer M.W., Rassweiler J.J., Klein J. et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol 2015;33(12):1937–43. DOI:10.1007/s00345-015-1568-6. PMID: 25910478.; Ковылина М.В., Прилепская Е.А., Тупикина Н.В. и др. Новое в стадировании уротелиальной карциномы мочевого пузыря. Онкоурология 2017;13(2):87–95. DOI:10.17650/1726-9776-2017-13-2-87-95.; Wolters M., Kramer M.W., Becker J.U. et al. Tm:YAG laser en bloc mucosectomy for accurate staging of primary bladder cancer: early experience. World J Urol 2011;29(4):429–32. DOI:10.1007/s00345-011-0686-z. PMID: 21553277.; Андреева Ю.Ю., Данилова Н.В., Москвина Л.В. и др. Опухоли мочевыделительной системы и мужских половых органов. Морфологическая диагностика и генетика. Руководство для врачей. Под. ред. Ю.Ю. Андреевой, Г.А. Франка. М.: Практическая медицина , 2012. 216 с.; Compe´rat E.M., Burger M., Gontero P. et. a l. Grading of urothelial carcinoma and the new “World Health Organisation classification of tumours of the urinary system and male genital organs 2016”. Eur Urol Focus 2018.; Younes M., Sussman J., True L.D. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66(3):543–8. PMID: 2364365.; van Rhijn B.W., Liu L., Vis A.N. et al. Prognostic value of molecular markers, substage and European Organisation for the Research and Treatment of cancer risk scores in primary T1 bladder cancer. BJU Int 2012;110(8):1169–76. DOI:10.1111/j.1464-410X2012.10996.x.; van Rhijn B.W., van der Kwast T.H., Alkhateeb S.S. et. a l. A new and highly prognostic system to research T1 bladder cancer substage. Eur Urol 2012;61(2):378–84. DOI:10.1016/j.eururo.2011.10.026. PMID: 22036775.; https://oncourology.abvpress.ru/oncur/article/view/838Test